RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3): clinical trials recruiting now

Fewer than 3 recruiting trials found.

1

Recruiting trials

2

Conditions studied

3

US states with sites

1

Countries

Phase breakdown

Phase 1 1

Conditions being studied

Condition	Trials
Dilated Cardiomyopathy (DCM)	1
Heart failure	1

Recruiting trials involving RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3)

A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy
NCT07137338 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 3 locations

Common questions

How many recruiting trials involve RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3)?

1 recruiting trial across 2 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.